Paeds SAQs · clinical-pharmacology-and-therapeutics
Cardiovascular medicines in children — formative SAQs
Formative SAQs on cardiovascular medicines in children: designing a prostaglandin E1 resuscitative plan for a duct-dependent neonate, and building the stepwise pharmacological management of paediatric heart failure with the carvedilol and single-ventricle enalapril trial evidence in mind.
On this page & tools
Target exams
SAQ 1 — A cyanotic neonate and prostaglandin E1 (10 marks, 15 minutes)
Stem: A two-day-old term neonate presents with central cyanosis, tachypnoea and a metabolic acidosis. There is strong clinical suspicion of a duct-dependent congenital heart lesion, and echocardiography is being arranged. Outline the immediate pharmacological management, the dose, the target, and the adverse effects you must prepare for. [10]
Model answer
Immediate action (2 marks). Do not wait for echocardiography. Start an intravenous prostaglandin E1 (alprostadil) infusion at once, because the circulation depends on a patent ductus arteriosus that is closing. Prostaglandin E1 reopens and keeps the duct patent while definitive anatomy-specific management is arranged. Secure intravenous access, give oxygen, and prepare for transfer to a cardiac centre. [10]
Dose and titration (3 marks). Start at 0.01 to 0.05 microgram per kilogram per minute intravenously and titrate upward toward a typical maximum of around 0.1 microgram per kilogram per minute, watching for the response: a rising oxygen saturation, a warming perfusion, and a falling lactate. The target saturation in most duct-dependent cyanotic disease is around 75 to 85 per cent, not a normal saturation, because excessive pulmonary flow steals from the systemic circulation. State that prostaglandin E1 is a bridge, not a treatment. [10]
Adverse effects and preparation (3 marks). Three adverse effects are expected and prepared for. Apnoea is common — have a plan for intubation and ventilation. Fever can mislead the team toward a septic work-up; recognise it as a drug effect. Hypotension is managed with volume and, where needed, a low-dose vasopressor. Recognise that the fever and apnoea are the drug, not the disease. [10]
Safety and disposition (2 marks). Treat the prostaglandin as a bridge to definitive anatomy repair or palliation. Communicate clearly with the family, organise retrieval to a cardiac centre, and document the dose, the titration and the airway plan. Do not allow suspicion of sepsis to delay the prostaglandin, but take appropriate cultures and consider antibiotics alongside. [10]
You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References4Show ledgerHide ledger
- [2]Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA, 2007.PMID 17848651
- [3]Hsu DT, Zak V, Mahony L, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation, 2010.PMID 20625111
- [4]Hsu DT, Pearson GD Heart failure in children: part II: diagnosis, treatment, and future directions. Circ Heart Fail, 2009.PMID 19808380
- [10]Taksande A, Jameel PZ Critical Congenital Heart Disease in Neonates: A Review Article. Curr Pediatr Rev, 2021.PMID 33605861